This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered In-Person & Digitally
March 28–30, 2022, Basel, SwitzerlandApril 4–6, 2022, Digital Partnering

Cameron Durrant
Chairman and CEO at Humanigen, Inc.

Profile

Cameron Durrant is currently the Chairman and CEO of Humanigen, which is developing a monoclonal antibody therapy that is now being considered for use in the treatment of COVID-19. Since 2016, Cameron has led the company through several critical transformations, the most recent being adapting to the global pandemic.

Cameron has extensive experience heading public and private companies, with his specialty being start-ups and leading major company turnarounds. His therapeutic area of expertise is in infectious diseases, oncology, CAR-T, and pediatrics. Prior to working at Humanigen, Cameron has served in executive roles at Johnson & Johnson, Pharmacia, PediaMed, and Hi-Tech Pharmacal. He is also the founder of Taran Pharma, specializing in urology, and PediatRx, marketing FDA-approved therapies for pediatric orphan drugs and oncology supportive care. With multiple citizenships in the United States and the United Kingdom, he has had the opportunity to live and work in the biopharma industry in several countries.

Agenda Sessions

  • Pandemic therapeutics: treating COVID-19 and beyond

    17:00